Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 690517 plus empagliflozin in chronic kidney disease
CTR20250809Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vicadrostat, empagliflozin in chronic kidney disease (CKD), sponsored by Boehringer Ingelheim. Started Nov 2025; status: terminated.
02
Drugs
vicadrostatempagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20250809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250809.